Clinical Trials Logo

16P11.2 Deletion Syndrome clinical trials

View clinical trials related to 16P11.2 Deletion Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04271332 Active, not recruiting - Clinical trials for 16P11.2 Deletion Syndrome

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This Phase 2 study examines the safety, tolerability, and efficacy of arbaclofen in pediatric subjects with 16p11.2 deletion. Male or female subjects aged 5 to 17 years of age will be randomized to receive either placebo or arbaclofen in a double-blind study design. If the subject completes all study requirements through Visit 4 (Close-out Visit), he/she may be eligible for an optional open-label study with arbaclofen.